Adeno-Associated Virus (AAV) gene therapy for cystic fibrosis: current barriers and recent developments

Research output: Contribution to journalReview articlepeer-review

Abstract

Introduction: Since the cystic fibrosis (CF) gene was discovered in 1989, researchers have worked to develop a gene therapy. One of the most promising and enduring vectors is the AAV, which has been shown to be safe. In particular, several clinical trials have been conducted with AAV serotype 2. All of them detected viral genomes, but identification of mRNA transduction was not consistent; clinical outcomes in Phase II studies were also inconsistent. The lack of a positive outcome has been attributed to a less-than-efficient viral infection by AAV2, a weak transgene promoter and the host immune response to the vector. Areas covered: Herein, the authors focus on AAV gene therapy for CF, evaluating past experience with this approach and identifying ways forward, based on the progress that has already been made in identifying and overcoming the limitations of AAV gene therapy. Expert opinion: Such progress makes it clear that this is an opportune time to push forward toward the development of a gene therapy for CF. Drugs to treat the basic defect in CF represent a remarkable advance but cannot treat a significant cohort of patients with rare mutations. Thus, there is a critical need to develop a gene therapy for those individuals.

Original languageEnglish (US)
Pages (from-to)1265-1273
Number of pages9
JournalExpert Opinion on Biological Therapy
Volume17
Issue number10
DOIs
StatePublished - Oct 3 2017

Keywords

  • Gene therapy
  • adeno-associated virus
  • clinical trials
  • cystic fibrosis
  • preclinical testing

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Fingerprint Dive into the research topics of 'Adeno-Associated Virus (AAV) gene therapy for cystic fibrosis: current barriers and recent developments'. Together they form a unique fingerprint.

Cite this